Trejo-Vargas Aglaé, Hernández-Mercado Elisa, Ordóñez-Razo Rosa María, Lazzarini Roberto, Arenas-Aranda Diego Julio, Gutiérrez-Ruiz María Concepción, Königsberg Mina, Luna-López Armando
Departamento de Ciencias de la Salud, DCBS, Universidad Autónoma Metropolitana Iztapalapa, México, D.F., México.
Unidad Médica en Genética Humana, Centro Médico Nacional Siglo XXI, México, D.F., Mexico.
J Appl Toxicol. 2015 Nov;35(11):1262-70. doi: 10.1002/jat.3173. Epub 2015 Jun 9.
Cancer chemotherapy remains one of the preferred therapeutic modalities against malignancies despite its damaging side effects. An expected outcome while utilizing chemotherapy is apoptosis induction. This is mainly regulated by a group of proteins known as the Bcl-2 family, usually found within the endoplasmic reticulum or the mitochondria. Recently, these proteins have been located in other sites and non-canonic functions have been unraveled. Bik is a pro-apoptotic protein, which becomes deregulated in cancer, and as apoptosis is associated with oxidative stress generation, our objective was to determine the subcellular localization of Bik either after a direct oxidative insult due to H2 O2 , or indirectly by cisplatin, an antineoplastic agent. Experiments were performed in two human transformed mammary gland cell lines MDA-MB-231 and MCF-7, and one non-tumorigenic epithelial cell line MCF-10A. Our results showed that in MCF-7, Bik is localized within the cytosol and that after oxidative stress treatment it translocates into the nucleus. However, in MDA-MB-231, Bik localizes in the nucleus and translocates to the cytosol. In MCF10A Bik did not change its cellular site after either treatment. Interestingly, MCF10A were more resistant to cisplatin than transformed cell lines. This is the first report showing that Bik is located in different cellular compartments depending on the cancer stage, and it has the ability to change its subcellular localization in response to oxidative stress. This is associated with increased sensitivity when exposed to toxic agents, thus rendering novel opportunities to study new therapeutic targets allowing the development of more active and less harmful agents.
尽管癌症化疗存在有害的副作用,但它仍然是治疗恶性肿瘤的首选方法之一。使用化疗的一个预期结果是诱导细胞凋亡。这主要由一组称为Bcl-2家族的蛋白质调节,这些蛋白质通常存在于内质网或线粒体中。最近,这些蛋白质已被定位到其他部位,并且其非经典功能也已被揭示。Bik是一种促凋亡蛋白,在癌症中会失调,由于细胞凋亡与氧化应激的产生有关,我们的目标是确定在受到H2O2直接氧化损伤后或通过抗肿瘤药物顺铂间接诱导后Bik的亚细胞定位。实验在两个人类转化乳腺细胞系MDA-MB-231和MCF-7以及一个非致瘤性上皮细胞系MCF-10A中进行。我们的结果表明,在MCF-7中,Bik定位于细胞质中,氧化应激处理后它会转移到细胞核中。然而,在MDA-MB-231中,Bik定位于细胞核中并转移到细胞质中。在MCF10A中,两种处理后Bik的细胞定位均未改变。有趣的是,MCF10A比转化细胞系对顺铂更具抗性。这是第一份报告表明Bik根据癌症阶段位于不同的细胞区室中,并且它有能力响应氧化应激改变其亚细胞定位。这与暴露于有毒剂时敏感性增加有关,从而为研究新的治疗靶点提供了新机会,有助于开发更有效且危害更小的药物。